Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ipilimumab + tumor-infiltrating lymphocytes
- Development stage
- Unknown
- Lead developer
- Moffitt Cancer Center
- Modality
- Cell Therapies, Cytokines & Interferons → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This investigational combination therapy regimen was developed and evaluated by the H. Lee Moffitt Cancer Center and Research Institute for the treatment of metastatic melanoma. The protocol combines the administration of ipilimumab, a monoclonal antibody that inhibits the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) checkpoint, with adoptive cell therapy using autologous tumor-infiltrating lymphocytes (TILs). The treatment process typically involves a pre-treatment phase with ipilimumab to enhance the immune environment, followed by surgical tumor harvest for ex vivo TIL expansion. Patients then undergo a lymphodepletion phase using chemotherapy (cyclophosphamide and fludarabine) before receiving the TIL infusion and high-dose interleukin-2 (IL-2) to support T-cell persistence and anti-tumor activity. This multi-modality approach aims to overcome immune suppression and maximize the effector function of tumor-reactive T cells.
- Other names
- ipilimumab + TILsipilimumab + TIL + IL-2
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on ipilimumab + tumor-infiltrating lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ipilimumab + tumor-infiltrating lymphocytes.